Everest Medicines Valuation
Is 1952 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1952 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1952 (HK$25.45) is trading below our estimate of fair value (HK$29.63)
Significantly Below Fair Value: 1952 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1952?
Other financial metrics that can be useful for relative valuation.
What is 1952's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥7.43b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.5x |
Enterprise Value/EBITDA | -5.7x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1952's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.7x | ||
6855 Ascentage Pharma Group International | 13.1x | 20.0% | HK$13.0b |
2696 Shanghai Henlius Biotech | 2x | 10.4% | HK$12.4b |
9966 Alphamab Oncology | 14.3x | 39.4% | HK$4.0b |
1875 TOT BIOPHARM International | 1.4x | 20.5% | HK$1.5b |
1952 Everest Medicines | 17.8x | 37.2% | HK$8.2b |
Price-To-Sales vs Peers: 1952 is expensive based on its Price-To-Sales Ratio (17.8x) compared to the peer average (7.7x).
Price to Earnings Ratio vs Industry
How does 1952's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 1952 is expensive based on its Price-To-Sales Ratio (17.8x) compared to the Hong Kong Biotechs industry average (11.4x).
Price to Sales Ratio vs Fair Ratio
What is 1952's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 17.8x |
Fair PS Ratio | 8.6x |
Price-To-Sales vs Fair Ratio: 1952 is expensive based on its Price-To-Sales Ratio (17.8x) compared to the estimated Fair Price-To-Sales Ratio (8.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | HK$25.45 | HK$26.14 +2.7% | 6.9% | HK$29.90 | HK$24.52 | n/a | 6 |
Oct ’25 | HK$27.15 | HK$26.14 -3.7% | 6.9% | HK$29.90 | HK$24.52 | n/a | 6 |
Sep ’25 | HK$20.70 | HK$26.23 +26.7% | 7.5% | HK$30.30 | HK$24.49 | n/a | 6 |
Aug ’25 | HK$19.40 | HK$26.08 +34.5% | 7.6% | HK$29.81 | HK$24.04 | n/a | 6 |
Jul ’25 | HK$19.58 | HK$28.12 +43.6% | 18.3% | HK$39.88 | HK$23.98 | n/a | 7 |
Jun ’25 | HK$22.05 | HK$28.12 +27.5% | 18.3% | HK$39.88 | HK$23.98 | n/a | 7 |
May ’25 | HK$24.45 | HK$28.05 +14.7% | 18.5% | HK$39.96 | HK$24.03 | n/a | 7 |
Apr ’25 | HK$23.50 | HK$28.05 +19.4% | 18.5% | HK$39.96 | HK$24.03 | n/a | 7 |
Mar ’25 | HK$24.25 | HK$26.28 +8.4% | 22.6% | HK$40.11 | HK$21.16 | n/a | 7 |
Feb ’25 | HK$16.22 | HK$26.38 +62.6% | 22.3% | HK$40.13 | HK$21.17 | n/a | 7 |
Jan ’25 | HK$20.90 | HK$26.61 +27.3% | 23.0% | HK$40.18 | HK$18.63 | n/a | 7 |
Dec ’24 | HK$20.05 | HK$26.67 +33.0% | 22.9% | HK$40.22 | HK$18.65 | n/a | 7 |
Nov ’24 | HK$29.75 | HK$22.34 -24.9% | 13.1% | HK$25.60 | HK$18.26 | n/a | 6 |
Oct ’24 | HK$25.00 | HK$22.34 -10.6% | 13.1% | HK$25.60 | HK$18.26 | HK$27.15 | 6 |
Sep ’24 | HK$18.10 | HK$22.51 +24.4% | 14.7% | HK$28.74 | HK$18.01 | HK$20.70 | 7 |
Aug ’24 | HK$21.05 | HK$21.93 +4.2% | 21.4% | HK$28.99 | HK$15.31 | HK$19.40 | 7 |
Jul ’24 | HK$23.80 | HK$21.82 -8.3% | 22.0% | HK$29.00 | HK$15.31 | HK$19.58 | 7 |
Jun ’24 | HK$10.82 | HK$21.97 +103.0% | 21.1% | HK$28.20 | HK$15.54 | HK$22.05 | 7 |
May ’24 | HK$14.22 | HK$24.15 +69.8% | 25.0% | HK$34.97 | HK$16.00 | HK$24.45 | 8 |
Apr ’24 | HK$15.44 | HK$24.68 +59.9% | 22.6% | HK$34.56 | HK$17.13 | HK$23.50 | 8 |
Mar ’24 | HK$18.28 | HK$24.68 +35.0% | 22.3% | HK$34.43 | HK$15.65 | HK$24.25 | 9 |
Feb ’24 | HK$25.60 | HK$24.61 -3.9% | 23.3% | HK$34.89 | HK$14.27 | HK$16.22 | 9 |
Jan ’24 | HK$17.38 | HK$23.19 +33.4% | 28.9% | HK$34.15 | HK$13.66 | HK$20.90 | 9 |
Dec ’23 | HK$11.12 | HK$22.60 +103.2% | 29.1% | HK$33.27 | HK$13.31 | HK$20.05 | 9 |
Nov ’23 | HK$6.60 | HK$22.57 +242.0% | 29.4% | HK$33.14 | HK$13.27 | HK$29.75 | 9 |
Oct ’23 | HK$7.50 | HK$22.49 +199.9% | 28.9% | HK$33.21 | HK$13.30 | HK$25.00 | 9 |
Analyst Forecast: Target price is less than 20% higher than the current share price.